Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $70.03 Million |
|---|---|
| Enterprise Value | $61.20 Million |
| Earnings per Share | $-1.65 |
| Beta | 1.86 |
| Outstanding Shares | 36,750,000 |
| P/E Ratio | -1.41 |
|---|---|
| PEG | 2.1 |
| Price to Sales | - |
| Price to Book Ratio | -1.97 |
| Enterprise Value to Revenue | 31.08 |
| Enterprise Value to EBIT | -1.43 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.09 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 12.40%▼ 37.84% |
|---|---|
| Total Invested | $16.36M▼ 84.98% |
| Investors Holding | 28▼ 13.00% |
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the Uni...